Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Nasdaq lags on angst over AI spending ahead of earnings reports
Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus
February 6, 2020 4:45 PM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($1.69), $0.86 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $17.16 million versus the consensus estimate of $16.07 million.
FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS
Orders: Total orders received for the first quarter of fiscal 2020 were $24.8 million, compared to $15.2 million for the same period of fiscal 2019.Revenue: Total revenues were $17.2 million for the first quarter of fiscal 2020 compared to $11.5 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the first quarter of fiscal 2020 was $13.8 million... More